As a milestone breakthrough of stem cell and regenerative medicine in recent years, somatic cell reprogramming has opened up new applications of regenerative medicine by breaking through the ethical shackles of embryo...As a milestone breakthrough of stem cell and regenerative medicine in recent years, somatic cell reprogramming has opened up new applications of regenerative medicine by breaking through the ethical shackles of embryonic stern cells. However, induced pluripo- tent stem （iPS） cells are prepared with a complicated protocol that results in a low reprogramming rate. To obtain differentiated target cells, iPS cells and embryonic stem cells still need to be induced using step-by-step procedures. The safety of induced target cells from iPS cells is currently a further concerning matter. More broadly conceived is lineage reprogramming that has been investigated since 1987. Adult stem cell plasticity, which triggered interest in stem cell research at the end of the last century, can also be included in the scope of lineage reprogramming. With the promotion of iPS cell research, lineage reprogramming is now considered as one of the most promising fields in regenerative medicine, will hopefully lead to customized, personalized therapeutic options for patients in the future.展开更多
Parkinson’s disease is typically characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta.Many studies have been performed based on the supplementation of lost dopaminergic ...Parkinson’s disease is typically characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta.Many studies have been performed based on the supplementation of lost dopaminergic neurons to treat Parkinson’s disease.The initial strategy for cell replacement therapy used human fetal ventral midbrain and human embryonic stem cells to treat Parkinson’s disease,which could substantially alleviate the symptoms of Parkinson’s disease in clinical practice.However,ethical issues and tumor formation were limitations of its clinical application.Induced pluripotent stem cells can be acquired without sacrificing human embryos,which eliminates the huge ethical barriers of human stem cell therapy.Another widely considered neuronal regeneration strategy is to directly reprogram fibroblasts and astrocytes into neurons,without the need for intermediate proliferation states,thus avoiding issues of immune rejection and tumor formation.Both induced pluripotent stem cells and direct reprogramming of lineage cells have shown promising results in the treatment of Parkinson’s disease.However,there are also ethical concerns and the risk of tumor formation that need to be addressed.This review highlights the current application status of cell reprogramming in the treatment of Parkinson’s disease,focusing on the use of induced pluripotent stem cells in cell replacement therapy,including preclinical animal models and progress in clinical research.The review also discusses the advancements in direct reprogramming of lineage cells in the treatment of Parkinson’s disease,as well as the controversy surrounding in vivo reprogramming.These findings suggest that cell reprogramming may hold great promise as a potential strategy for treating Parkinson’s disease.展开更多
Human embryonic stem cells(hESCs)are pluripotent cells that have the ability of unlimited self-renewal and can be differentiated into different cell lineages,includ-ing neural stem(NS)cells.Diverse regulatory signalin...Human embryonic stem cells(hESCs)are pluripotent cells that have the ability of unlimited self-renewal and can be differentiated into different cell lineages,includ-ing neural stem(NS)cells.Diverse regulatory signaling pathways of neural stem cells differentiation have been discovered,and this will be of great benefit to uncover the mechanisms of neuronal differentiation in vivo and in vitro.However,the limitations of hESCs resource along with the religious and ethical concerns impede the pro-gress of ESCs application.Therefore,the induced pluri-potent stem cells(iPSCs)via somatic cell reprogramming have opened up another new territory for regenerative medicine.iPSCs now can be derived from a number of lin-eages of cells,and are able to differentiate into certain cell types,including neurons.Patient-specifi c iPSCs are being used in human neurodegenerative disease modeling and drug screening.Furthermore,with the development of somatic direct reprogramming or lineage reprogramming technique,a more effective approach for regenerative medicine could become a complement for iPSCs.展开更多
基金supported by the National High Technology Research and Development Program of China (2011AA020109)the National Basic Research Program of China (2011CB964804)
文摘As a milestone breakthrough of stem cell and regenerative medicine in recent years, somatic cell reprogramming has opened up new applications of regenerative medicine by breaking through the ethical shackles of embryonic stern cells. However, induced pluripo- tent stem （iPS） cells are prepared with a complicated protocol that results in a low reprogramming rate. To obtain differentiated target cells, iPS cells and embryonic stem cells still need to be induced using step-by-step procedures. The safety of induced target cells from iPS cells is currently a further concerning matter. More broadly conceived is lineage reprogramming that has been investigated since 1987. Adult stem cell plasticity, which triggered interest in stem cell research at the end of the last century, can also be included in the scope of lineage reprogramming. With the promotion of iPS cell research, lineage reprogramming is now considered as one of the most promising fields in regenerative medicine, will hopefully lead to customized, personalized therapeutic options for patients in the future.
基金supported by the National Natural Science Foundation of China,No.31960120Yunnan Science and Technology Talent and Platform Plan,No.202105AC160041(both to ZW).
文摘Parkinson’s disease is typically characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta.Many studies have been performed based on the supplementation of lost dopaminergic neurons to treat Parkinson’s disease.The initial strategy for cell replacement therapy used human fetal ventral midbrain and human embryonic stem cells to treat Parkinson’s disease,which could substantially alleviate the symptoms of Parkinson’s disease in clinical practice.However,ethical issues and tumor formation were limitations of its clinical application.Induced pluripotent stem cells can be acquired without sacrificing human embryos,which eliminates the huge ethical barriers of human stem cell therapy.Another widely considered neuronal regeneration strategy is to directly reprogram fibroblasts and astrocytes into neurons,without the need for intermediate proliferation states,thus avoiding issues of immune rejection and tumor formation.Both induced pluripotent stem cells and direct reprogramming of lineage cells have shown promising results in the treatment of Parkinson’s disease.However,there are also ethical concerns and the risk of tumor formation that need to be addressed.This review highlights the current application status of cell reprogramming in the treatment of Parkinson’s disease,focusing on the use of induced pluripotent stem cells in cell replacement therapy,including preclinical animal models and progress in clinical research.The review also discusses the advancements in direct reprogramming of lineage cells in the treatment of Parkinson’s disease,as well as the controversy surrounding in vivo reprogramming.These findings suggest that cell reprogramming may hold great promise as a potential strategy for treating Parkinson’s disease.
基金the National Basic Research Program 973 program(No.2012CB966800)the Thousand Youth Talents Program and the Pioneer Programs of Chinese Academy of Sciences。
文摘Human embryonic stem cells(hESCs)are pluripotent cells that have the ability of unlimited self-renewal and can be differentiated into different cell lineages,includ-ing neural stem(NS)cells.Diverse regulatory signaling pathways of neural stem cells differentiation have been discovered,and this will be of great benefit to uncover the mechanisms of neuronal differentiation in vivo and in vitro.However,the limitations of hESCs resource along with the religious and ethical concerns impede the pro-gress of ESCs application.Therefore,the induced pluri-potent stem cells(iPSCs)via somatic cell reprogramming have opened up another new territory for regenerative medicine.iPSCs now can be derived from a number of lin-eages of cells,and are able to differentiate into certain cell types,including neurons.Patient-specifi c iPSCs are being used in human neurodegenerative disease modeling and drug screening.Furthermore,with the development of somatic direct reprogramming or lineage reprogramming technique,a more effective approach for regenerative medicine could become a complement for iPSCs.
